67392-87-4 Categories: ,
  • # LGM Pharma is a Drospirenone CAS# 67392-87-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Drospirenone
  • CAS #: 67392-87-4
  • Mode of Action:

    Progestins such as drospirenone diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

  • Pharmacodynamics:

    Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic.

  • Metabolism:

    Extensively metabolized following oral or intravenous administration. The two major metabolites are inactive and are formed independent of the CYP450 enzyme system. The metabolites are the acid form of drospirenone formed by opening of the lactone ring and the 4, 5-dihydro-drospirenone-3-sulfate.

  • IUPAC: (1R, 2R, 4R, 10R, 11S, 14S, 15S, 16S, 18S, 19S)-10, 14-dimethylspiro[hexacyclo[, {2, 4}.0, {5, 10}.0, {14, 19}.0, {16, 18}]nonadecane-15, 2'-oxolan]-5-ene-5', 7-dione
  • PubChem: 68873
  • DrugBank: DB01395
  • Formula: C23H31Cl2NO3
  • Molecular Mass: 366.4932
  • Synonyms: 6_,7_,15_,16_-dimethylene-3-oxo-17_-pregn-4-ene-21,17 carbolactone Drospirenona [inn-spanish] Drospirenonum [inn-latin] DRSP
  • SMILES: C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1
  • AHFS Code: 68:12:00
  • General Reference:


    1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. Pubmed


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service